Nalaganje...

吉非替尼治疗EGFR基因突变状态不明的青年晚期肺腺癌疗效分析

BACKGROUND AND OBJECTIVE: Lung cancer in young patients (less or equal to 45 years) is relatively rare. We explored the efficacy and survival of Gefitinib for young patients with unknown epidermal growth factor receptor (EGFR) gene mutation of advanced lung adenocarcinoma. METHODS: The clinical data...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Zhongguo Fei Ai Za Zhi
Format: Artigo
Jezik:Inglês
Izdano: 中国肺癌杂志编辑部 2014
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6000448/
https://ncbi.nlm.nih.gov/pubmed/24854557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2014.05.06
Oznake: Označite
Brez oznak, prvi označite!